Reminder: Circio invites to circular RNA R&D webinar today
Oslo, Norway, 29 November 2023 – Circio Holding ASA (OSE: CRNA) Circio's management invites to a live R&D webinar featuring a KOL presentation by circular RNA pioneer and founder of oRNA Therapeutics, Dr. Alexander Wesselhoeft, today at 10am EST / 4pm CET.
Webinar details:
| Date: | Wednesday 29 November 2023 |
| Time: | 10am EST / 4pm CET, duration ~75-90 minutes |
| Webinar link: | Click here for webinar link |
In the webinar Circio´s management will provide a company update and review of the circVec R&D program, and Dr. Wesselhoeft will provide a general perspective on circRNA biology and the market landscape.
Agenda:
|
Dr. Erik D Wiklund, CEO Circio |
|
Dr. R. Alexander Wesselhoeft, Director of RNA Therapeutics, Gene and Cell Therapy Institute, Mass General Brigham, Cambridge USA |
|
Dr. Victor Levitsky, CSO Circio |
|
Dr. Thomas B Hansen, VP & Head of Research Circio |
Questions can be submitted in advance to renate.birkeli@circio.com or directly during the live webinar.
For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@circio.com
About Circio
Building next generation RNA therapeutics
Circio Holding ASA is a biotechnology company developing novel circular RNA and immunotherapy medicines.
Circio has established a unique circular RNA (circRNA) platform to develop novel circRNA medicines for rare disease, vaccines, and cancer. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA and viral vectors, which can be deployed for many purposes. The circVec platform has demonstrated enhanced and more durable protein expression than classic mRNA vector systems, and has the potential to become the new gold-standard for DNA and virus-based therapeutics in the future. The circRNA R&D activities are being conducted by the wholly owned subsidiary Circio AB based at the Karolinska Institute in Stockholm, Sweden.
In addition, Circio is developing a cancer vaccine, TG01, targeting KRAS driver mutations. TG01 is currently being tested in two clinical trials in RAS-mutated pancreatic cancer and multiple myeloma in the USA and Norway. These studies are being run through academic collaborative networks, supported by prestigious research grants from Innovation Norway and the Norwegian Research Council, creating read-outs and future optionality for the program at low cost to Circio.